此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

联合化疗和盐酸普纳替尼治疗急性淋巴细胞白血病

2026年10月5日 更新者:M.D. Anderson Cancer Center

费城 (PH) 染色体阳性和/或 BCR-ABL 阳性急性淋巴细胞白血病 (ALL) 患者联合使用 Hyper-CVAD 和普纳替尼的 II 期研究

This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.

研究概览

地位

主动,不招人

条件

干预/治疗

详细说明

PRIMARY OBJECTIVES:

I. To evaluate the clinical efficacy (event-free survival) of an intensive short-term chemotherapy regimen (hyperfractionated cyclophosphamide-vincristine sulfate-Adriamycin [doxorubicin hydrochloride]-dexamethasone [hyper-CVAD] program) given in combination with the tyrosine kinase inhibitor ponatinib hydrochloride (ponatinib) for Philadelphia (Ph)-positive and/or BCR-ABL-positive acute lymphoblastic leukemia (ALL).

II. To evaluate other clinical efficacy endpoints (overall response rate and survival) and safety of the regimen.

OUTLINE:

ODD CYCLES (1, 3, 5, and 7): Patients receive cyclophosphamide intravenously (IV) over 3 hours every 12 hours on days 1-3, doxorubicin hydrochloride IV continuously over 24 hours on day 4, vincristine sulfate IV over 30 minutes on days 1 and 11, dexamethasone IV over 30 minutes or orally (PO) once daily (QD) on days 1-4 and 11-14, and ponatinib hydrochloride PO QD on days 1-14 of cycle 1 and continuously in cycles 3, 5, and 7. Patients with CD20 expression may also receive rituximab IV on days 1 and 11 of cycle 1 and 3. Treatment repeats every 3-4 weeks for up to 8 cycle in the absence of disease progression or unacceptable toxicity.

EVEN CYCLES (2, 4, 6, and 8): Patients receive methotrexate IV over 24 hours on day 1, ponatinib hydrochloride PO QD continuously, and cytarabine IV over 3 hours every 12 hours on days 2 and 3. Patients with CD20 expression may also receive rituximab IV on days 1 and 8 of cycle 2 and 4. Treatment repeats every 3-4 weeks for up to 8 cycle in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive vincristine sulfate IV on day 1, prednisone PO daily on days 1-5, and ponatinib hydrochloride PO QD on days 1-28. Cycle repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 6 months for up to 24 months.

研究类型

介入性

注册 (实际的)

88

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • M D Anderson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of one of the following:

    • Previously untreated Ph-positive ALL [either t(9;22) and/or bcr-abl positive] (includes patients initiated on first course of hyper-CVAD before cytogenetics known) or with lymphoid accelerated or blast phase chronic myelogenous leukemia (CML)

    • Previously treated Ph-positive ALL or CML (in accelerated phase or blast phase), after 1-2 courses of chemotherapy with or without other tyrosine kinase inhibitors (TKIs)

      • If they achieved complete response (CR), they are assessable only for event-free and overall survival, or
      • If they failed to achieve CR, they are assessable for CR, event-free, and overall survival
  • Performance status ≤ 2 (Eastern Cooperative Oncology Group [ECOG] scale, Appendix E)

  • Adequate liver function as defined by the following criteria:

  • Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome

  • Alanine aminotransferase (ALT) ≤ 2 x ULN

  • Aspartate aminotransferase (AST) ≤ 2.5 x ULN

  • Adequate pancreatic function as defined by the following criteria:

  • Serum lipase and amylase ≤ 1.5 x ULN

  • For females of childbearing potential, a negative pregnancy test must be documented prior to randomization

  • Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment

  • Adequate cardiac function as assessed clinically by history and physical examination

  • Signed informed consent

Exclusion Criteria:

  • Active serious infection not controlled by oral or intravenous antibiotics

  • History of acute pancreatitis within 1 year of study or history of chronic pancreatitis

  • History of alcohol abuse

  • Uncontrolled hypertriglyceridemia (triglycerides > 450 mg/dL)

  • Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year

  • Active grade III-V cardiac failure as defined by the New York Heart Association criteria

  • Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

    • Any history of myocardial infarction (MI), stroke, or revascularization
    • Unstable angina or transient ischemic attack prior to enrollment
    • Congestive heart failure prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment
    • Diagnosed or suspected congenital long QT syndrome
    • Any history of clinically significant atrial or ventricular arrhythmias (such as atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes) as determined by the treating physician
    • Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 470 msec) unless corrected after electrolyte replacement
    • Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
    • Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140 mmHg); patients with hypertension should be under treatment on study entry to effect blood pressure control
  • Patients currently taking drugs that are generally accepted to have a risk of causing torsades de pointes (unless these can be changed to acceptable alternatives)

  • Taking any medications or herbal supplements that are known to be strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) within at least 14 days before the first dose of ponatinib

  • Prior history of treatment with ponatinibfor > 1 month; patient who has been treated with ponatinib for 1 month prior starting the treatment is eligible

  • Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator; patient who has been treated with ponatinib for 1 month prior starting the treatment is eligible

  • Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception; women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control

  • History of significant bleeding disorder unrelated to cancer, including:

    • Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
    • Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
  • Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (combination chemotherapy, ponatinib hydrochloride)

See Detailed Description.

Correlative studies

Given IV

其他名称:
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦,2-[双(2-氯乙基)氨基]四氢-,2-氧化物,一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719

Given IV

其他名称:
  • 阿霉素
  • 5,12-并萘二酮,10-[(3-氨基-2,3,6-三脱氧-α-L-来氧代-己吡喃糖基)氧基]-7,8, 9,10-四氢-6,8,11-三羟基-8-(羟基乙酰基)-1-甲氧基-, 盐酸盐, (8S-cis)- (9CI)
  • 广告管理公司
  • 盐酸阿霉素
  • 阿霉素 PFS
  • 阿霉素RDF
  • 阿霉素,盐酸盐
  • Adriblastina
  • 阿得拉碱
  • 阿地美达
  • 氯霉素
  • DOX
  • DOXO细胞
  • 多索伦
  • 农杆菌
  • FI 106
  • FI-106
  • 羟基柔红霉素
  • 橡胶

Given PO

其他名称:
  • 达美松
  • 奥拉松
  • .delta.1-可的松
  • 1, 2-脱氢可的松
  • 阿达松
  • 皮质醇
  • 达考汀
  • 德考坦
  • 去氧硫醇
  • 德克顿
  • Delta 1-可的松
  • 三角穹顶
  • 三角可烯
  • 三角可的松
  • 三角洲脱氢可的松
  • 德尔蒂森
  • 三角洲
  • 经济松
  • 利沙克特
  • 美保生-F
  • 麦考坦
  • 奥菲索罗纳
  • 帕纳福特
  • 松脂-S
  • 伞骨
  • 预测
  • 泼尼松-M
  • 泼尼可特
  • 泼尼地布
  • 泼尼龙加
  • 预付款
  • 泼尼松
  • 泼尼通
  • 普罗米芬
  • 伺服松
  • SK-泼尼松

Given IV

其他名称:
  • .beta.-阿糖胞苷
  • 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-.beta.-D-阿拉伯呋喃糖基胞嘧啶
  • 1-β-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-β-D-阿拉伯呋喃糖基胞嘧啶
  • 1.beta.-D-阿拉伯呋喃糖基胞嘧啶
  • 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
  • 亚历山大
  • 阿糖胞苷C
  • ARA细胞
  • 阿拉伯语
  • 阿拉伯呋喃糖基胞嘧啶
  • 阿糖基胞嘧啶
  • 阿糖胞苷
  • 阿拉伯胞苷
  • 阿胞苷
  • CHX-3311
  • 赛塔贝尔
  • Cytosar
  • 胞嘧啶阿拉伯糖苷
  • 胞嘧啶-.beta.-阿拉伯糖苷
  • 胞嘧啶-β-阿拉伯糖苷
  • 艾帕法
  • 斯塔拉西德
  • 他拉宾 PFS
  • U 19920
  • U-19920
  • 乌迪西尔
  • WR-28453
  • Β-胞嘧啶阿拉伯糖苷

Given IV or PO

其他名称:
  • 十进制
  • 酸检验
  • 阿地松
  • Aknichthol Dexa
  • Alba-Dex
  • 阿林
  • 阿林得宝
  • 阿林·奥夫塔尔米科
  • 羊皮
  • 银莲花
  • 木耳
  • 辅助素
  • 贝库腾
  • 贝库腾 N
  • 皮质激素
  • 皮质素
  • 迪卡特
  • 癸二酚
  • 蜡纸
  • 十杀
  • 十卡松 R.p.
  • 癸烷基
  • 地卡可特
  • Δ芴
  • 德罗尼尔
  • 地塞米松
  • 地美通
  • Dexa-Mamallet
  • Dexa-Scheroson公司
  • 地塞辛
  • 皮质醇
  • 地塞法玛
  • 右旋芴
  • 右心醛
  • 地塞因
  • 恐龙兽
  • 氟代尔塔
  • 复方皮质素
  • 伽马考腾
  • 十六酚
  • 己二醇
  • Lokalison-F
  • 情人
  • 甲基氟泼尼松龙
  • 米利克顿
  • 米米松
  • Orgadrone
  • Spersadex
  • 维舒美松

Given IV

其他名称:
  • 阿德里亚斯汀
  • 羟基柔红霉素

Given IV

其他名称:
  • 阿比曲沙
  • 福莱克斯
  • 梅赛特
  • 甲氨蝶呤
  • 甲氧蝶呤
  • 氨甲蝶呤
  • 溴甲磺酸
  • CL 14377
  • CL-14377
  • Emtexate
  • 艾美泰
  • 消融剂
  • 农美曲沙
  • Fauldexato
  • 福莱克斯全氟辛烷磺酸
  • 兰塔雷尔
  • 莱德曲沙
  • Lumexon公司
  • 麦克斯曲斯
  • 美泰克斯
  • 美白素
  • 甲氨蝶呤LPF
  • 甲氨蝶呤甲氨蝶呤
  • 美特捷
  • Mexate-AQ
  • 诺瓦特雷克斯
  • 风湿曲
  • 得克萨斯
  • 混纺
  • 曲克塞隆
  • 三锡林
  • WR-19039

Given PO

其他名称:
  • AP-24534
  • AP24534

Given PO

其他名称:
  • AP24534 盐酸盐
  • 包括

Given IV

其他名称:
  • 利妥昔单抗
  • 美罗华
  • 总部基地 798
  • BI 695500
  • C2B8单克隆抗体
  • 嵌合抗 CD20 抗体
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8单克隆抗体
  • 单克隆抗体IDEC-C2B8
  • PF-05280586
  • 利妥昔单抗生物类似药 ABP 798
  • 利妥昔单抗生物仿制药 BI 695500
  • 利妥昔单抗生物类似药 CT-P10
  • 利妥昔单抗生物类似药 GB241
  • 利妥昔单抗生物仿制药 IBI301
  • 利妥昔单抗生物仿制药 PF-05280586
  • 利妥昔单抗生物类似药 RTXM83
  • 利妥昔单抗生物仿制药 SAIT101
  • RTXM83

Given IV

其他名称:
  • 录像机
  • 长春新碱
  • 亮新碱

Given IV

其他名称:
  • 致癌素
  • 基克里斯汀
  • 硫酸白新碱
  • 长春
  • 长春甙
  • 万可乐
  • 硫酸长春新碱
  • 硫酸亮绿新碱

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Event-free survival
大体时间:The time from the start of the treatment until any failure (resistant disease, relapse, or death), assessed up to 24 months

Kaplan-Meier survival curves will be constructed.

The time from the start of the treatment until any failure (resistant disease, relapse, or death), assessed up to 24 months

次要结果测量

结果测量
措施说明
大体时间
Complete response rate
大体时间:Up to 24 months after completion of study treatment

Complete response is defined as achieving bone marrow blasts =< 5% AND platelets >= 100 AND absolute neutrophil count >= 1000 within 3 courses of treatment. The method of Thall, Simon, and Estey will be employed to perform short-term interim efficacy. Response rate and its corresponding 95% confidence interval will be provided at the end of the study.

Up to 24 months after completion of study treatment
Incidence of grade 3-4 toxicity according to the M.D. Anderson Leukemia-specific Adverse Event Recording and Reporting Guidelines
大体时间:Up to 24 months

The method of Thall, Simon, and Estey will be employed to perform short-term interim safety monitoring. Will be summarized in frequency tables or in the form of mean, standard deviation, and range where appropriate. Toxicity rate and its corresponding 95% confidence interval will be provided at the end of the study.

Up to 24 months
Overall survival
大体时间:Up to 24 months after completion of study treatment

Kaplan-Meier survival curves will be constructed. Survival rates at specific time points will be estimated along with corresponding 95% confidence intervals.

Up to 24 months after completion of study treatment
Disease-specific survival
大体时间:Up to 24 months after completion of study treatment

Kaplan-Meier survival curves will be constructed. Survival rates at specific time points will be estimated along with corresponding 95% confidence intervals.

Up to 24 months after completion of study treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Elias Jabbour、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2011年10月5日

初级完成 (估计的)

2027年10月31日

研究完成 (估计的)

2027年10月31日

研究注册日期

首次提交

2011年8月24日

首先提交符合 QC 标准的

2011年8月26日

首次发布 (估计的)

2011年8月29日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月5日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2011-0030
  • 2011-0030 (其他标识符:M D Anderson Cancer Center)
  • NCI-2011-02941 (注册表标识符:CTRP (Clinical Trial Reporting Program))

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.